Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome [PDF]
Journal of Comparative Effectiveness Research, 2023 Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden.
Teri Mauch +2 more
exaly +4 more sources
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab [PDF]
Annals of Clinical and Translational NeurologyObjective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG)
Lea Gerischer +14 more
doaj +4 more sources
Ravulizumab exposure in early pregnancy [PDF]
Annals of HematologyBefore complement inhibitors were available, pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) was associated with considerable mortality, mainly due to thromboembolism.
Wolfgang Füreder +3 more
doaj +3 more sources
Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab [PDF]
Kidney International ReportsIntroduction: Atypical hemolytic uremic syndrome (aHUS) is a progressive rare disease that, if untreated, can result in severe organ damage and death.
Franz Schaefer +5 more
doaj +3 more sources
Therapeutic Advances in Hematology, 2020 Background: Ravulizumab, the only long-acting complement C5 inhibitor for adults with paroxysmal nocturnal hemoglobinuria (PNH), demonstrated non-inferiority to eculizumab after 26 weeks of treatment in complement inhibitor-naïve patients during a phase ...
Hubert Schrezenmeier +2 more
exaly +2 more sources
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study [PDF]
Annals of HematologyRavulizumab is a second-generation C5i engineered from eculizumab to achieve immediate, complete, and sustained inhibition of terminal complement activity in PNH.
Anna Paola Iori +35 more
doaj +2 more sources
Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder [PDF]
Neurology and TherapyIntroduction Anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) is a complement-mediated autoimmune disease in which unpredictable and relapsing attacks on the central nervous system cause irreversible and ...
Stacey L. Clardy +10 more
doaj +2 more sources
Case Report: COVID-19 unmasks factor H mutation-driven hemolytic uremic syndrome in a previously undiagnosed septuagenarian kidney transplant recipient [PDF]
Frontiers in MedicineThrombotic microangiopathy (TMA) after kidney transplantation presents a significant diagnostic and therapeutic challenge. Complement-mediated thrombotic microangiopathy (CM-TMA), caused by dysregulation of the alternative complement pathway, is ...
Michael Fink +5 more
doaj +2 more sources
Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment [PDF]
Blood Advances: In patients with paroxysmal nocturnal hemoglobinuria (PNH), the complement component 5 (C5) inhibitors ravulizumab and eculizumab control terminal complement activity and intravascular hemolysis, which are drivers of morbidity and mortality.
Austin G. Kulasekararaj +10 more
doaj +2 more sources
Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis. [PDF]
Clin TransplantIntroduction: Atypical hemolytic uremic syndrome (aHUS) is a disease of complement dysregulation that may lead to kidney failure. Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of aHUS.
Gaeckler A +7 more
europepmc +3 more sources